Title: Performance characteristics of the VIDAS® SARS-COV-2 IgM and IgG serological assays

Running title: VIDAS® SARS-COV-2 IgM and IgG assay performance

Nathalie Renard[a#], Soizic Daniel[a], Nadège Cayet[a], Matthieu Pecquet[b], Frédérique Raymond[a], Sylvie Pons[c], Julien Lupo[d], Carole Tourneur[a], Catherine Pretis[a], Guillaume Gerez[a], Patrick Blasco[a], Maxime Combe[a], Imen Canova[a], Mylène Lesénéchal[a#], Franck Berthier[a]

[a]R&D bioMérieux, 376 Chemin de l'orme, 69280 Marcy l'Etoile, FRANCE

[b]Laboratoire de Biologie, Centre Hospitalier Saint Joseph Saint Luc, 20 Quai Claude Bernard, 69007 Lyon, FRANCE

[c]Laboratoire commun de recherche Hospices Civils de Lyon - bioMérieux, Centre Hospitalier Lyon-Sud, Bâtiment 3F, Chemin du Grand Revoyet, 69310 Pierre-Bénite, FRANCE

[d]Institut de Biologie Structurale (IBS), CEA, CNRS, Université Grenoble-Alpes; Laboratoire de Virologie, Centre hospitalier Universitaire Grenoble-Alpes, CS10217, 38043 Grenoble cedex 09, FRANCE

[#]Nathalie Renard : Nathalie.RENARD@biomerieux.com

[#]Mylène Lesénéchal : mylene.lesenechal@biomerieux.com

ABSTRACT

The COVID-19 pandemic, caused by the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to spread worldwide. Serological testing for SARS-CoV-2-specific antibodies plays an important role in understanding and controlling the pandemics, notably through epidemiological surveillance. Well validated and highly specific SARS-CoV-2 serological assays are urgently needed. We describe here the analytical and clinical performance of VIDAS® SARS-CoV-2 IgM and VIDAS® SARS-CoV-2 IgG, two CE-marked, EUA-authorized, automated, qualitative assays for the detection of SARS-CoV-2-specific IgM and IgG, respectively. Both assays showed high within-run and within-laboratory precision (coefficients of variation < 11.0%) and very low cross-reactivity towards sera of patients with a past common coronavirus or respiratory virus infection. Clinical specificity determined on up to 989 pre-pandemic healthy donors was ≥ 99% with a narrow 95% confidence interval for both IgM and IgG assays. Clinical sensitivity was determined on up to 232 samples from 130 RT-PCR-confirmed SARS-CoV-2 patients. The positive percent agreement (PPA) with SARS-CoV-2 PCR reached 100% at ≥ 16 days (VIDAS® SARS-CoV-2 IgM) and ≥ 32 days (VIDAS® SARS-CoV-2 IgG) of symptom onset. Combined IgM/IgG test results improved the PPA compared to each test alone. SARS-CoV-2 IgG seroconversion followed closely that of SARS-CoV-2 IgM and remained stable over time, while SARS-CoV-2 IgM levels rapidly declined. Interestingly, SARS-CoV-2-specific IgM and IgG responses were significantly higher in COVID-19 hospitalized vs. non-hospitalized patients. Altogether, the VIDAS® SARS-CoV-2 IgM and IgG assays are highly specific and sensitive serological tests suitable for the reliable detection of past acute SARS-CoV-2 infections.

43 **INTRODUCTION**

44 Coronavirus disease 19 (COVID-19) is an infectious disease caused by the newly discovered
45 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (1, 2). Within three months of its
46 emergence in China in December 2019, COVID-19 has been declared a global pandemic by the
47 World Health Organisation (WHO). As of October 29, 2020, nearly 45 million COVID-19 cases
48 and 1.2 million deaths have been reported worldwide (3–5). Accurate diagnosis is essential in
49 managing the pandemic, not only to identify, isolate and treat affected patients, but also to
50 characterize the epidemiology of virus transmission and develop national and international
51 surveillance programs. WHO recommends molecular testing of SARS-CoV-2 nucleic acids for
52 acute-phase diagnosis of suspected cases (6–8). Several nucleic acid amplification tests (NAATs),
53 mostly based on quantitative reverse transcriptase polymerase chain reaction (RT-qPCR), have
54 received the Conformité Européenne (CE) mark and have been approved by the United States
55 Food and Drug Administration (FDA) under emergency use authorization (EUA) (9–11). On the
56 other hand, serological testing for SARS-CoV-2-specific antibodies, especially immunoglobulin M
57 (IgM) and immunoglobulin G (IgG), is not recommended as the primary method for the
58 diagnosis of acute cases. It plays however an essential role in the diagnosis of past SARS-CoV-2
59 infection and in ongoing immunological and epidemiological surveillance. Serological testing
60 might also complement molecular testing to confirm suspected cases not detected by molecular
61 assays, either due to late (> 7 days after infection) or improper sample collection. Finally,
62 serology screening may allow the identification of convalescent plasma donors for use as
63 potential therapy against COVID-19 (9–18).

64 SARS-CoV-2 serological testing is facing several challenges. Among them, sensitivity and
65 specificity should be well defined for the target population and validated at different post-
66 infection time windows. Specificity is particularly critical in the current pandemic phase, as
67 seroprevalence in the population is still low. In such low-incidence settings, a specificity > 99%
68 and a narrow 95% confidence interval (95% CI) are required to ensure a high positive predictive
69 value (PPV) (11, 19, 20). Accordingly, the antigens used to design serology tests should be
70 properly selected and cross-reactivity with antibodies directed against other antigens, including
71 from other coronaviruses, should be verified. A huge number of serology assays have been
72 developed and marketed in the last few months, of which 56 received FDA's EUA (as of October
73 29, 2020) (21, 22). Clinical performance data of commercial tests are still scant, and examples of
74 poorly performing tests have even been reported (9). Therefore, there is an urgent need for well
75 validated and performant serology tests, notably demonstrating very high specificity.

76 We describe here the analytical and clinical performance of VIDAS® SARS-CoV-2 IgM and VIDAS®
77 SARS-CoV-2 IgG, two CE-marked and EUA-authorized automated qualitative assays for the
78 detection of SARS-CoV-2-specific IgM and IgG, respectively, in serum or plasma. Kinetics of
79 SARS-CoV-2-specific IgM and IgG seroconversion using the VIDAS® SARS-CoV-2 IgM and VIDAS®
80 SARS-CoV-2 IgG assays were also compared in hospitalized and non-hospitalized COVID-19
81 patients.

82 **MATERIALS AND METHODS**

83 **Patients and samples.**

84 SARS-CoV-2-positive samples were collected after approval by the Ethics Committee RCB 2020-
85 A00932-37. Informed consent was obtained in accordance with the local regulations. Pre-
86 pandemic samples (from healthy subjects and from donors with other medical conditions) were
87 collected in accordance with the Declaration of Helsinki, as revised in 2013. Collected sera and
88 plasma were stored frozen (< -20°C) until further testing.

89 Serum from up to 989 healthy pre-pandemic adult donors collected before September 2019 at
90 two geographical sites (Etablissement Français du Sang (EFS), France; Clinilabs, Inc., United
91 States) were used to determine the assay specificity of the VIDAS® SARS-CoV-2 IgM, IgG and
92 combined IgM/IgG test (defined as negative if both VIDAS® SARS-CoV-2 IgM and IgG assays are
93 negative).

94 For the evaluation of the positive percent agreement (PPA), 405 serum or plasma samples from
95 142 symptomatic patients (60 hospitalized, 61 non-hospitalized, 21 of unknown hospitalization
96 status) diagnosed with COVID-19 and confirmed positive for SARS-CoV-2 by molecular testing
97 (cobas® SARS-CoV-2, Roche 09175431190 or Real-time RT-PCR assays for the detection of SARS-
98 CoV-2 Institut Pasteur, Paris (23), performed at the collection site) (Fig. 1) were collected at
99 three local hospitals (Centre Hospitalier Saint Joseph Saint Luc, Lyon, France; Centre de
100 Ressources Biologiques [CRB] des Hospices Civils de Lyon, CRB Nord and CRB Sud, Lyon, France)
101 between March 31 and June 2, 2020. Samples were tested with the VIDAS® SARS-CoV-2 IgM and
102 IgG assays, and paired measurements were considered for the combined IgM/IgG test results

103 (defined as positive if at least one of the VIDAS® SARS-CoV-2 IgM and/or IgG assays is positive)
104 (Fig. 1). The PPA was evaluated according to weekly time frames (0-7, 8-15, 16-23, 24-31, ≥ 32
105 days) relative to the time from RT-PCR positive result and from symptom onset, when
106 documented (Fig. 1).

107 For the evaluation of serum cross-reactivity, up to 276 frozen pre-pandemic sera (i.e. negative
108 for SARS-CoV-2) collected from patients with other potentially interfering infections or medical
109 conditions (bioMérieux, Centre Hospitalier Universitaire Grenoble-Alpes and St Joseph St Luc
110 Lyon collections) were tested with the VIDAS® SARS-CoV-2 IgM (276 sera from 33 medical
111 conditions; one to 30 sera per condition) and the VIDAS® SARS-CoV-2 IgG (261 sera from 33
112 medical conditions; two to 30 sera per condition) assays.

113

114 **Serological assays.**

115 VIDAS® SARS-CoV-2 IgM (423833) and VIDAS® SARS-CoV-2 IgG (423834) (bioMérieux, France)
116 are automated qualitative CE-IVD assays developed for the VIDAS® family of instruments and
117 based on a two-step enzyme immunoassay combined with an enzyme-linked fluorescent assay
118 (ELFA) detection technique. The VIDAS® SARS-CoV-2 IgM and VIDAS® SARS-CoV-2 IgG assays are
119 intended for use as an aid to determine if individuals may have been exposed and infected by
120 SARS-CoV-2 and if they have mounted a specific anti-SARS-CoV-2 IgM and IgG immune
121 response. These assays allow the detection of SARS-CoV-2-specific IgM and IgG, respectively,
122 from 100 µl serum or plasma (lithium heparin). The VIDAS® SARS-CoV-2 IgM and VIDAS® SARS-
123 CoV-2 IgG serological assays were conducted according to the manufacturer's instructions.

124 Briefly, a solid-phase receptacle coated with the antigen (recombinant SARS-CoV-2 receptor-
125 binding domain [RBD] of the viral Spike protein) serves as both solid phase and pipetting device.
126 After the sample dilution step, SARS-CoV-2-specific IgM and IgG are captured on the coated
127 antigen and unbound components are washed out. In a second step, human IgM (VIDAS® SARS-
128 CoV-2 IgM) or IgG (VIDAS® SARS-CoV-2 IgG) are specifically detected by mouse monoclonal
129 antibodies conjugated to alkaline phosphatase and directed against human IgM or IgG,
130 respectively. Unbound components are eliminated by washing and detection is performed by
131 incubation with the substrate (4-Methyl-umbelliferyl phosphate) followed by measurement of
132 the fluorescent product (4-Methyl-umbelliferone) at 450 nm. A relative fluorescence value (RFV)
133 is generated (background reading subtracted from the final fluorescence reading). The assay is
134 conducted with a standard (S1) and a positive control (C1) that contains humanized
135 recombinant anti-SARS-CoV-2 antibody, either IgM or IgG depending on the assay. A negative
136 control (C2) is also supplied. The results are automatically calculated by the instrument,
137 according to the S1 standard, and an index value (i) is obtained (where $i=RFV_{sample}/RFV_{S1}$). The
138 test is interpreted as negative when $i < 1.00$ and positive when $i \geq 1.00$. The positivity cut-off
139 values for the IgM and IgG tests were determined from a healthy pre-pandemic cohort (259
140 [IgM test] and 120 [IgG test] samples collected prior to August 2019), using non-parametric 99th
141 percentile because of normality rejection for the IgM positivity cut-off and using the (99,99)
142 tolerance intervals approach after Box-Cox transformation (24) for the IgG positivity cut-off (99th
143 percentile index values at a 99% confidence level) (data not shown).

144

145

146

147 **Statistical analysis.**

148 Assay precision was evaluated according to the Clinical & Laboratory Standards Institute (CLSI)
149 EP05-A3 guideline (25) by the variance component method and restricted maximum likelihood
150 (REML) using the SAS Enterprise Guide 7.13 HF8 software.

151 Specificity and sensitivity (PPA) estimates were evaluated according to the CLSI EP12-A2
152 guideline (26). The 95% confidence intervals (95% CI) were computed (either as score
153 confidence interval if the specificity or sensitivity (PPA) belonged to] 5 ; 95[%, or as exact
154 confidence interval otherwise) using the SAS Enterprise Guide 7.13 HF8 software.

155 PPA was evaluated per time windows (in days) relative to the day of RT-PCR positive result and
156 of symptom onset (when documented). To avoid a statistical bias, only one patient's
157 measurement per time period was included in the analysis. In case of multiple patient's
158 measurements in one period, the first available measurement was considered for the
159 calculation. Therefore, depending on the total number of longitudinal tests performed, each
160 patient contributed with one to five test results in the five time windows considered (0-7, 8-15,
161 16-23, 24-31, ≥ 32 days).

162 The positive predictive value (PPV) and the negative predictive value (NPV) were calculated
163 assuming a prevalence of 5%, as recommended by FDA for the EUA application (22), and the
164 respective 95% CI were computed according to Mercaldo et al. (27) using the SAS Enterprise
165 Guide 7.13 HF8 software.

166 VIDAS® SARS-CoV-2 index values were displayed per time frame as Tukey box plots. Two-group
167 comparisons of index values per time frame between hospitalized and non-hospitalized patients
168 were performed using the nonparametric two-tailed Mann-Whitney *U*-test (MWU-test) with
169 normal approximation. In case of multiple group comparisons, the Bonferroni method was
170 applied for controlling the 5% overall probability of a false-significant result. Accordingly, for the
171 three-group comparison shown in Figure 3, *P*-values < 0.017 were considered statistically
172 significant.

173

174 **RESULTS**

175 **Analytical performance of VIDAS® SARS-CoV-2 IgM and IgG assays**

176 Within-run and within-laboratory precisions of the ELFA-based tests were determined using
177 three samples (one negative and two positive for SARS-CoV-2 IgM and IgG). Samples were run in
178 triplicate on one VIDAS® instrument, twice a day over 10 days (with an instrument calibration
179 every second day), using one assay lot, thus generating 60 measurement values per sample. The
180 coefficient of variation (%CV) for repeatability (within-run precision) did not exceed 9.3% and
181 5.9% for the VIDAS® SARS-CoV-2 IgM and IgG assays, respectively. The %CV for within-laboratory
182 precision was also low, reaching a maximum of 10.7% and 6.9% for the VIDAS® SARS-CoV-2 IgM
183 and IgG assays, respectively (Table S1).

184 Analytical specificity and sensitivity of the VIDAS® SARS-CoV-2 IgM and IgG assays were verified
185 through various experiments. First, we ruled out a possible cross-reactivity of the anti-human-
186 IgM (VIDAS® SARS-CoV-2 IgM) or of the anti-human-IgG (VIDAS® SARS-CoV-2 IgG) with human
187 IgG or IgM, respectively, which might produce false-positive results. Spike-in experiments in
188 negative samples using either human recombinant monoclonal anti-SARS-CoV-2 IgG (10 µg/ml)
189 in the VIDAS® SARS-CoV-2 IgM assay or human recombinant monoclonal anti-SARS-CoV-2 IgM (3
190 µg/ml) in the VIDAS® SARS-CoV-2 IgG assay demonstrated neither reactivity of the alkaline-
191 phosphatase-conjugated anti-human-IgM toward human IgG nor reactivity of the anti-human-
192 IgG toward human IgM (n=10; data not shown). Second, we ruled out a possible competition
193 between anti-SARS-CoV-2 IgM and IgG for binding to the coated SARS-CoV-2 antigen, which
194 might interfere with the respective assays and generate false-negative results. Spike-in
195 experiments in positive samples (with index values ranging from 1.8 to 20.6) using an excess of

196 human recombinant monoclonal anti-SARS-CoV-2 IgG (10 µg/ml) in the VIDAS® SARS-CoV-2 IgM
197 assay or of human recombinant monoclonal anti-SARS-CoV-2 IgM (3 µg/ml) in the VIDAS® SARS-
198 CoV-2 IgG assay did not impact the qualitative test results and resulted in a maximum deviation
199 from the respective control of 17.6% (n=12; data not shown). Third, we evaluated the impact of
200 serum inactivation (56°C for 30 minutes), which might be applied by diagnostics laboratories to
201 inactivate potentially infectious samples (28), on test results of 10 negative and 10 positive
202 samples. Heat inactivation did not impact the qualitative test results of the VIDAS® SARS-CoV-2
203 IgM and IgG assays (20/20 = 100% concordance) and the maximum deviation to the (non-
204 heated) control among 18/20 samples was 17%. However, one negative sample (VIDAS® SARS-
205 CoV-2 IgG) and one positive sample (VIDAS® SARS-CoV-2 IgM) yielded significantly divergent
206 index values (data not shown). Therefore heat inactivation of sera prior to VIDAS® SARS-CoV-2
207 testing should be preferably avoided. Finally, we evaluated the possible cross-reactivity of
208 components of the assay (SARS-CoV-2 antigen RBD or immunoglobulins) with human sera from
209 patients with other infections (including other coronaviruses) or medical conditions (e.g.
210 rheumatoid factor) (29) that might interfere with the assay and yield false-positive results. Up to
211 276 (VIDAS® SARS-CoV-2 IgM) and 261 (VIDAS® SARS-CoV-2 IgG) sera of SARS-CoV-2-negative
212 patients with other infections or conditions were tested and the number of positive test results
213 was evaluated (Table 1). None of the 18 sera of patients with an history of infection with the
214 human coronaviruses CoV-NL63, CoV-229E, CoV-HKU1 or CoV-OC43 (genera *Alphacoronavirus*
215 and *Betacoronavirus*) were positive in the VIDAS® SARS-CoV-2 IgG assay, while the serum of one
216 CoV-NL63-positive patient was positive in the VIDAS® SARS-CoV-2 IgM assay. Only two out of
217 261 (0.8%) tested sera were positive in the VIDAS® SARS-CoV-2 IgG assay. They belonged to a

218 HIV-positive and a respiratory syncytial virus (RSV A)-positive patient, respectively. On the other
219 hand, ten out of 276 (3.6%) tested sera were positive in the VIDAS® SARS-CoV-2 IgM assay. Apart
220 from the one CoV-NL63-positive sample mentioned above, six sera were from patients
221 presenting autoantibodies (antinuclear antibody, rheumatoid factor), two were from patients
222 with an history of parasite infection (*Plasmodium falciparum*, *Trypanosoma cruzi*), and one from
223 a past Rhinovirus/Enterovirus infection. The index values associated with these 12 crossreactive
224 sera was low, with a median (interquartile range) of 2.1 (1.4-3.8). None of the sera from
225 patients infected with other respiratory viruses, including influenza virus, parainfluenza virus,
226 metapneumovirus or adenovirus were reactive.

227

228 **Clinical performance of VIDAS® SARS-COV-2 IgM and IgG assays**

229 The clinical specificity of the VIDAS® SARS-CoV-2 IgM and IgG assays were assessed using sera
230 from up to 989 pre-pandemic healthy volunteers collected in France and in the United States
231 before September 2019. A total of 308 sera were tested with the VIDAS® SARS-CoV-2 IgM assay
232 and 989 sera were tested with the VIDAS® SARS-CoV-2 IgG assay. The combined IgM/IgG assay
233 specificity (defined as both VIDAS® SARS-CoV-2 IgM and IgG assays being negative) was
234 determined on 308 paired VIDAS® SARS-CoV-2 IgM and IgG tests (Tables S2 and S3). 306/308
235 (VIDAS® SARS-CoV-2 IgM) and 988/989 (VIDAS® SARS-CoV-2 IgG) SARS-CoV-2-negative sera were
236 negative, corresponding to a specificity (95% CI) of 99.4% (97.7-99.9%) and 99.9% (99.4-100%)
237 for the VIDAS® SARS-CoV-2 IgM and IgG assays, respectively (Table S3). The specificity (95% CI)
238 of the VIDAS® SARS-CoV-2 IgG test on the common cohort (N=308) was 100.0% (98.8-100.0%).

239 The specificity (95% CI) of the combined IgM and IgG serology tests (306/308 tests negative in
240 both assays) was 99.4% (97.7-99.9%) (Table S3).

241 The clinical sensitivity of the VIDAS® SARS-CoV-2 IgM and IgG assays was assessed using 405
242 samples collected from 142 patients confirmed positive for SARS-CoV-2 by RT-PCR. The positive
243 percent agreement (PPA) of the serology tests with the RT-PCR test results was calculated per
244 weekly time windows (0-7, 8-15, 16-23, 24-31 and ≥ 32 days) relative to the time from the PCR-
245 positive result and to the time from symptom onset. No more than one patient sample per time
246 window was included in the calculation (Fig. 1 and Table 2). The PPA calculated on all available
247 samples for the VIDAS® SARS-CoV-2 IgM and IgG assays are shown in Tables S4 and S5,
248 respectively. For the sake of comparability, the PPA (95% CI) of the IgM, IgG and combined
249 IgM/IgG test results was also calculated on samples evaluated with both tests (paired testing;
250 Tables 3, 4 and S6).

251 The PPA from the time of RT-PCR-positive test results for the VIDAS® SARS-CoV-2 IgM assay
252 raised from 44.5% at 0-7 days to 100.0% at 24-31 days, before decreasing to 81.8% at ≥ 32 days
253 (Table 3). The PPA for the VIDAS® SARS-CoV-2 IgG assay raised from 45.5% at 0-7 days to 100.0%
254 from day 24 onwards(Table 3). The PPA of the combined IgM and IgG serology tests (positive in
255 at least one of the IgM and/or IgG assays) from the time of RT-PCR-positive test results,
256 increased from 53.6% at 0-7 days to 100.0% from day 16 onwards (Tables 3 and S6). The PPA
257 evaluated relative to the time of symptom onset raised from 31.8% at 0-7 days (VIDAS® SARS-
258 CoV-2 IgM and IgG) to 100.0% from day 16 (VIDAS® SARS-CoV-2 IgM) or day 24 (VIDAS® SARS-
259 CoV-2 IgG) (Table 4). The PPA of the combined IgM and IgG serology test results from the time
260 of symptom onset, increased from 36.4% at 0-7 days to 100.0% from day 16 onwards (Tables 4

261 and S6). It should be noted that the PPA relative to the date of symptom onset is mainly based
262 on hospitalized patients (Table 2).

263 Based on the specificity and the PPA determined on paired IgM and IgG testing (N=308 for
264 specificity; N=105 for PPA), the negative predictive value (NPV) and the positive predictive value
265 (PPV) were calculated at 5% prevalence (22), according to the time after symptom onset (Table
266 5). The NPV was high for both the VIDAS® SARS-CoV-2 IgM and IgG assays, whether considered
267 alone or in combination; NPV was ≥ 96.5% (lower 95% confidence limits ≥ 95.4%) at 0-7 days
268 post symptom onset and NPV increased from 99.1% to 100.0% (lower 95% confidence limits ≥
269 98.0%) from day 8 onwards following symptom onset. The PPV of the VIDAS® SARS-CoV-2 IgG
270 assay was 100% at all time frames considered. Of note, the PPV calculated using the full data set
271 for the VIDAS® SARS-CoV-2 IgG specificity determination (N=989) was slightly lower, increasing
272 from 94.3% at 0-7 days to 98.1% at ≥ 32 days (Table S7). The PPV of the VIDAS® SARS-CoV-2 IgM
273 assay was lower, ranging from 72.1% at 0-7 days to 89.0% from day 16 onwards following
274 symptom onset (Table 5). The combination of IgM and IgG test results slightly improved the PPV
275 and NPV of the SARS-CoV-2 IgM assay, and the NPV of the SARS-CoV-2 IgG assay. The SARS-CoV-
276 2 IgG assay performed best alone in terms of PPV (Table 5).

277

278 **Longitudinal study of IgM and IgG seroconversion in hospitalized COVID-19 patients**

279 The global distribution of VIDAS® SARS-CoV-2 IgM and IgG index values post symptom onset was
280 compared among the 105 SARS-CoV-2-positive patients described in Table 4 (i.e. mainly
281 including hospitalized COVID-19 patients; Table 2) (Fig. 2). IgM index values increased from the

282 second week of symptom onset (8-15 days) and peaked during the third week (16-23 days)
283 before decreasing. In comparison, the IgG index values strongly increased from the second week
284 of symptom onset and seemed to reach a plateau ≥ 32 days post symptom onset (Fig. 2).

285 The VIDAS® SARS-CoV-2 IgM and IgG index values were also compared between hospitalized
286 and non-hospitalized patients. Since the date of symptom onset was not documented in non-
287 hospitalized patients (Table 2), the index values in 54 hospitalized and 61 non-hospitalized
288 patients were compared relative to the time of the RT-PCR-positive results (Fig. 3). Interestingly,
289 the distribution of index values between hospitalized and non-hospitalized patients differ
290 statistically from each other for both the VIDAS® SARS-CoV-2 IgM and IgG assays at the three
291 compared time frames (0-7, 8-15 and 16-23 days post PCR-positive test; MWU-test p-values <
292 0.017). Median index values were higher in hospitalized versus non-hospitalized patients (Fig.
293 3).

294 Finally, IgM and IgG seroconversion was further investigated in four selected hospitalized
295 patients with either early and/or repeated measurements over an extended period of time (up
296 to 74 days post symptom onset; Fig. 4). IgG seroconversion closely followed IgM seroconversion
297 in the second week of symptom onset (Fig. 4A-B), in line with the global profile shown in Figure
298 2. SARS-CoV-2 IgM index rapidly decreased concomitantly with the increase of SARS-CoV-2 IgG
299 index (Fig. 4B-D). In the three patients shown in Fig. 4B-D, SARS-CoV-2 IgM index decreased
300 below the positivity cutoff (index = 1.00) 46 days after symptom onset. In contrast, SARS-CoV-2
301 IgG index values remained high and stable from approximately day 20 onward after symptom
302 onset, at least up to 74 days.

303

304 **DISCUSSION**

305

306 We describe here the analytical and clinical performance of the VIDAS® SARS-CoV-2 IgM and IgG
307 assays. We demonstrate that both assays show high precision, and excellent analytical and
308 clinical performances.

309 The rate of cross-reactivity with non-specific antibodies, including those of patients infected
310 with other coronaviruses, was very low in both VIDAS® SARS-CoV-2 IgM and IgG assays. This
311 weak cross-reactivity with other coronaviruses antibodies is likely due, at least in part, to the
312 choice of the receptor-binding domain (RBD) of the viral Spike protein as SARS-CoV-2-specific
313 antigen. The RBD shows a high sensitivity in ELISA, higher than that of the SARS-CoV-2 spike S1
314 or nucleocapsid (NC) antigens (30–33). It also presents a weaker homology and significant
315 structural divergences with the RBD of other coronaviruses (34–36). Another advantage of using
316 the RBD is that the viral antigen generates neutralizing antibodies likely to provide protective
317 immunity (35–42), as previously demonstrated for SARS-CoV (43, 44). That the VIDAS® SARS-
318 CoV-2 assays have the ability to detect SARS-CoV-2 neutralizing antibodies was recently
319 demonstrated in mild COVID-19 patients, with an almost perfect concordance (Cohen's Kappa
320 coefficient of 0.9) between the VIDAS® SARS-CoV-2 IgG assay and a virus neutralization test (42).
321 Beside its strong immunogenicity and antigenicity, the RBD of SARS-CoV has been shown to
322 elicit antibody responses that persisted many years after infection (38, 44), raising the
323 possibility that it might also be the case for the RBD of SARS-CoV-2. Recent studies in COVID-19
324 patients, notably in convalescent donors (45–47), on the anti-RBD antibody dynamics post SARS-
325 CoV-2 infection (39, 40), or demonstrating the persistence and expansion of SARS-CoV-2-specific

326 memory lymphocytes (48), as well as the stability of the IgG response detected with the VIDAS®
327 SARS-CoV-2 IgG assay up to 74 days post-symptom onset in the present study, strongly support
328 this proposition. Hence, a serology test such as the VIDAS® SARS-CoV-2 IgG assay is likely to be
329 suitable for the detection of protective immunity and the evaluation of the efficacy of future
330 vaccines, which are mainly based on the RBD-containing Spike protein (49, 50).

331 The low cross-reactivity rate with non-specific sera probably explains the very high specificity (≥
332 99%) and narrow 95% CI of both VIDAS® SARS-CoV-2 IgM and IgG assays. The VIDAS® SARS-CoV-2
333 IgG assay alone had a specificity close to 100%, slightly higher than that of the VIDAS® SARS-CoV-
334 2 IgM assay.

335 The clinical sensitivity of the VIDAS® SARS-CoV-2 assays was evaluated in SARS-CoV-2-confirmed
336 symptomatic cases and was determined as positive percent agreement (PPA) with the RT-PCR
337 assay, at successive time frames post positive PCR and, alternatively, post symptom onset. The
338 PPA reached 100% at 16-23 days (VIDAS® SARS-CoV-2 IgM) and at ≥ 32 days (VIDAS® SARS-CoV-2
339 IgG) post-symptom onset. The combined VIDAS® SARS-CoV-2 IgM/IgG test evaluation improved
340 the PPA of the respective IgM and IgG tests by 3.5 to 6.9 percent points during the first two
341 weeks (0-7 and 8-15 days) of symptom onset. Such improved sensitivity of the combined
342 IgM/IgG tests early after symptom onset might also be useful for the diagnosis of suspected
343 COVID-19 cases with negative PCR (13–15, 17, 18).

344 Overall, the clinical performance of the VIDAS® SARS-CoV-2 assays was excellent. It was in a
345 range comparable to that reported for existing EUA serological assays (22, 33, 42, 51–57).
346 Moreover, in several side-by-side comparisons of six to nine commercial serological assays
347 (specific for SARS-CoV-2 IgA, IgM, IgG or total antibodies), VIDAS® SARS-CoV-2 IgG outperformed

348 some of the IgG-specific competitor assays in terms of specificity and/or PPA with PCR positivity
349 (42, 56, 57). The high specificity of the VIDAS® SARS-CoV-2 IgG assay alone should be well suited
350 for epidemiological surveillance.

351

352 The kinetics of SARS-CoV-2 IgM and IgG seroconversion was also evaluated by monitoring
353 VIDAS® index values over time. VIDAS® SARS-CoV-2 IgM and IgG index values increased in the
354 second week after symptom onset. IgG index values strongly increased and remained high, as
355 IgM index values rapidly declined. These profiles are in agreement with those described in
356 recent publications (13, 30, 39, 40, 58–62). Interestingly, the magnitude of the antibody
357 response (index values) correlated with disease severity, as it was significantly higher in
358 hospitalized vs. non-hospitalized COVID-19 patients at the time frames investigated (0-7, 18-15
359 and 16-23 days after a PCR-positive test). This observation is in agreement with published
360 reports (11, 40, 62–65). It should be noted that despite the significantly lower response of sera
361 from mild (non-hospitalized) COVID-19 patients in the VIDAS® SARS-CoV-2 assays (Fig. 3), the
362 good performance of the assays as well as their strong concordance with seroneutralization was
363 recently demonstrated in a cohort of mild COVID-19 patients (42).

364

365 This study presents several limitations. First, assay sensitivity was evaluated on confirmed but
366 not on suspected SARS-CoV-2 cases (i.e. patients with symptoms but negative by PCR). It would
367 be interesting to evaluate and confirm the benefit of SARS-CoV-2 IgM and IgG serology to
368 complement PCR testing (13, 14, 17, 18). On the other hand, recent reports suggested that the

369 identification rate of false-negative PCR results using serology testing might be marginal,
370 between ~1% (20) and ~4% (62). Second, assay sensitivity was determined on symptomatic
371 (hospitalized and non-hospitalized) COVID-19 patients. The sensitivity of the VIDAS® SARS-CoV-2
372 IgM and IgG assays in asymptomatic SARS-CoV-2-infected individuals, who may represent most
373 of the infected patients, remains to be evaluated.

374

375 In conclusion, VIDAS® SARS-CoV-2 IgM and IgG are highly sensitive and specific assays for the
376 reliable screening of patients after acute SARS-CoV-2 infections (and likely after vaccination,
377 when available). Moreover, the VIDAS® SARS-CoV-2 IgG assay fulfils the specificity requirement
378 for its use in seroepidemiology studies and is well suited for the detection of past SARS-CoV-2
379 infections. Further studies are necessary to confirm its suitability for the detection of SARS-CoV-
380 2 neutralizing antibodies and to define correlates of immune protection.

381 **ACKNOWLEDGMENTS**

382 This work was supported by bioMérieux. We thank the Etablissement Français du Sang, notably
383 Yves Mérieux, for providing samples. We thank all the members of R&D Immunoassay
384 bioMérieux who took part in this work, i.e. the bioMolecule Engineering team, Prototyping,
385 Development and Verification teams. We warmly thank Nadia Piga and the biobank team for
386 collecting the samples in a short time frame. We are grateful to the bioMérieux Data Sciences
387 team for the calculations and statistical evaluation of the data, and to Victor Bondanese,
388 Laurence Bridon and the Clinical Affairs team of bioMérieux for their help and technical support.
389 We thank Karen Brengel for her useful advices as well as Alice Banz for critically reading the
390 manuscript. The authors thank Dr. Anne Rascle of AR Medical Writing (Regensburg, Germany)
391 for providing medical writing support, which was funded by bioMérieux (Marcy L'Etoile, France)
392 in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).

393

394 Conflict of interests' statement

395 JL declares received research funding from bioMérieux for this study.

396 MP declares a consulting contract with bioMérieux.

397

398 Contributions

399 NR, SD, ML, CT, FB conceived the study; CP, GG, PB, MC conceived the study and performed the
400 serological assays. FR, SP, MP, JL collected patients' samples; NC, IC, NR, CT, ML, interpreted

401 the serological assays; all authors contributed to data acquisition, data analysis, and/or data

402 interpretation, and all authors reviewed and approved the final manuscript.

403

404 **REFERENCES**

405 1. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, Si H-R, Zhu Y, Li B, Huang C-L, Chen H-
406 D, Chen J, Luo Y, Guo H, Jiang R-D, Liu M-Q, Chen Y, Shen X-R, Wang X, Zheng X-S, Zhao K,
407 Chen Q-J, Deng F, Liu L-L, Yan B, Zhan F-X, Wang Y-Y, Xiao G-F, Shi Z-L. 2020. A pneumonia
408 outbreak associated with a new coronavirus of probable bat origin. Nature 579:270–273.

409 2. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. 2020.
410 The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV
411 and naming it SARS-CoV-2. Nat Microbiol 5:536–544.

412 3. World Health Organization. 2020. Coronavirus Disease (COVID-19) Situation Reports.
413 https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.
414 Accessed: October 29, 2020.

415 4. Dong E, Du H, Gardner L. 2020. An interactive web-based dashboard to track COVID-19 in
416 real time. Lancet Infect Dis 20:533–534.

417 5. Johns Hopkins University. 2020. COVID-19 Resource Center.
418 https://coronavirus.jhu.edu/map.html. Accessed: October 29, 2020.

419 6. World Health Organization. 2020. Laboratory testing for 2019 novel coronavirus (2019-
420 nCoV) in suspected human cases. https://www.who.int/publications-detail-redirect/10665-
421 331501. Accessed: October 29, 2020.

422 7. World Health Organization. 2020. Global surveillance for COVID-19 caused by human
423 infection with COVID-19 virus: interim guidance. https://www.who.int/publications-detail-

424 redirect/global-surveillance-for-covid-19-caused-by-human-infection-with-covid-19-virus-
425 interim-guidance. Accessed: October 29, 2020.

426 8. World Health Organization. 2020. Laboratory testing strategy recommendations for COVID-
427 19: interim guidance. https://www.who.int/publications-detail-redirect/laboratory-testing-
428 strategy-recommendations-for-covid-19-interim-guidance. Accessed: October 29, 2020.

429 9. Vashist SK. 2020. In Vitro Diagnostic Assays for COVID-19: Recent Advances and Emerging
430 Trends. Diagnostics 10:202.

431 10. Venter M, Richter K. 2020. Towards effective diagnostic assays for COVID-19: a review. J Clin
432 Pathol jclinpath-2020-206685.

433 11. Bohn MK, Lippi G, Horvath A, Sethi S, Koch D, Ferrari M, Wang C-B, Mancini N, Steele S,
434 Adeli K. 2020. Molecular, serological, and biochemical diagnosis and monitoring of COVID-
435 19: IFCC taskforce evaluation of the latest evidence. Clinical Chemistry and Laboratory
436 Medicine (CCLM) 58:1037–1052.

437 12. Winter AK, Hegde ST. 2020. The important role of serology for COVID-19 control. The Lancet
438 Infectious Diseases S1473309920303224.

439 13. Guo L, Ren L, Yang S, Xiao M, Chang D, Yang F, Dela Cruz CS, Wang Y, Wu C, Xiao Y, Zhang L,
440 Han L, Dang S, Xu Y, Yang Q, Xu S, Zhu H, Xu Y, Jin Q, Sharma L, Wang L, Wang J. 2020.
441 Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). Clin
442 Infect Dis https://doi.org/10.1093/cid/ciaa310.

443 14. Zhao R, Li M, Song H, Chen J, Ren W, Feng Y, Gao GF, Song J, Peng Y, Su B, Guo X, Wang Y,
444 Chen J, Li J, Sun H, Bai Z, Cao W, Zhu J, Zhang Q, Sun Y, Sun S, Mao X, Su J, Chen X, He A, Gao
445 W, Jin R, Jiang Y, Sun L. 2020. Early detection of SARS-CoV-2 antibodies in COVID-19 patients
446 as a serologic marker of infection. Clinical Infectious Diseases ciaa523.

447 15. Caruana G, Croxatto A, Coste AT, Opota O, Lamoth F, Jaton K, Greub G. 2020. Diagnostic
448 strategies for SARS-CoV-2 infection and interpretation of microbiological results. Clinical
449 Microbiology and Infection 26:1178–1182.

450 16. Pancrazzi A, Magliocca P, Lorubbio M, Vaggelli G, Galano A, Mafucci M, Duranti D, Cortesi
451 M, Mazzeschi E, Fabbroni S, Viti G, Tartaglia Polcini A, Tripodo E, Sanchini P, Gervino S,
452 Tacconi D, Dei S, Mazzierli M, D'Urso A, Ognibene A. 2020. Comparison of serologic and
453 molecular SARS-CoV 2 results in a large cohort in Southern Tuscany demonstrates a role for
454 serologic testing to increase diagnostic sensitivity. Clinical Biochemistry
455 S0009912020307918.

456 17. Zhang J, Zhang X, Liu J, Ban Y, Li N, Wu Y, Liu Y, Ye R, Liu J, Li X, Li L, Qin X, Zheng R. 2020.
457 Serological detection of 2019-nCoV respond to the epidemic: A useful complement to
458 nucleic acid testing. Int Immunopharmacol 88:106861.

459 18. Liu R, Liu X, Yuan L, Han H, Shereen MA, Zhen J, Niu Z, Li D, Liu F, Wu K, Luo Z, Zhu C. 2020.
460 Analysis of adjunctive serological detection to nucleic acid test for severe acute respiratory
461 syndrome coronavirus 2 (SARS-CoV-2) infection diagnosis. Int Immunopharmacol
462 86:106746.

463 19. Bryant JE, Azman AS, Ferrari MJ, Arnold BF, Boni MF, Boum Yap, Hayford K, Luquero FJ, Mina
464 MJ, Rodriguez-Barraquer I, Wu JT, Wade D, Vernet G, Leung DT. 2020. Serology for SARS-
465 CoV-2: Apprehensions, opportunities, and the path forward. Sci Immunol 5:eabc6347.

466 20. Farnsworth CW, Anderson NW. 2020. SARS-CoV-2 Serology: Much Hype, Little Data. Clinical
467 Chemistry hvaa107.

468 21. U.S. Food and Drug Administration. 2020. In Vitro Diagnostics EUAs.
469 https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-
470 authorizations-medical-devices/vitro-diagnostics-euas. Accessed: October 29, 2020.

471 22. U.S. Food and Drug Administration. 2020. EUA Authorized Serology Test Performance.
472 https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-
473 authorizations-medical-devices/eua-authorized-serology-test-performance. Accessed:
474 October 29, 2020.

475 23. World Health Organization. Real-time RT-PCR assays for the detection of SARS-CoV-2 Institut
476 Pasteur, Paris. https://www.who.int/nepal/activities/supporting-elimination-of-kala-azar-as-
477 a-public-health-problem/docs/default-source/coronaviruse/real-time-rt-pcr-assays-for-the-
478 detection-of-sars-cov-2-institut-pasteur-paris. Accessed: October 29, 2020.

479 24. Dong X, Tsong Y, Shen M. 2015. Statistical considerations in setting product specifications. J
480 Biopharm Stat 25:280–294.

481 25. Clinical & Laboratory Standards Institute. EP05-A3: Evaluating Quantitative Measurement
482 Precision, 3rd Edition. https://clsi.org/standards/products/method-
483 evaluation/documents/ep05/. Accessed: October 29, 2020.

484 26. Clinical & Laboratory Standards Institute. EP12-A2: User Protocol for Evaluation of
485 Qualitative Test Performance, 2nd Edition. https://clsi.org/standards/products/method-
486 evaluation/documents/ep12/. Accessed: October 29, 2020.

487 27. Mercaldo ND, Lau KF, Zhou XH. 2007. Confidence intervals for predictive values with an
488 emphasis to case-control studies. Stat Med 26:2170–2183.

489 28. Pastorino B, Touret F, Gilles M, de Lamballerie X, Charrel RN. 2020. Heat Inactivation of
490 Different Types of SARS-CoV-2 Samples: What Protocols for Biosafety, Molecular Detection
491 and Serological Diagnostics? Viruses 12:735.

492 29. Tate J, Ward G. 2004. Interferences in immunoassay. Clin Biochem Rev 25:105–120.

493 30. Ma H, Zeng W, He H, Zhao D, Yang Y, Jiang D, Zhou P, Qi Y, He W, Zhao C, Yi R, Wang X,
494 Wang B, Xu Y, Yang Y, Kombe AJK, Ding C, Xie J, Gao Y, Cheng L, Li Y, Ma X, Jin T. 2020.
495 COVID-19 diagnosis and study of serum SARS-CoV-2 specific IgA, IgM and IgG by
496 chemiluminescence immunoanalysis. medRxiv 2020.04.17.20064907.

497 31. Okba NMA, Müller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM, Lamers MM,
498 Sikkema RS, de Bruin E, Chandler FD, Yazdanpanah Y, Le Hingrat Q, Descamps D, Houhou-
499 Fidouh N, Reusken CBEM, Bosch B-J, Drosten C, Koopmans MPG, Haagmans BL. 2020.

500 Severe Acute Respiratory Syndrome Coronavirus 2–Specific Antibody Responses in
501 Coronavirus Disease 2019 Patients. Emerg Infect Dis 26.

502 32. Liu W, Liu L, Kou G, Zheng Y, Ding Y, Ni W, Wang Q, Tan L, Wu W, Tang S, Xiong Z, Zheng S.
503 2020. Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent
504 Assays for Detecting Antibodies against SARS-CoV-2. Journal of Clinical Microbiology
505 58:e00461-20.

506 33. Lassaunière R, Frische A, Harboe ZB, Nielsen AC, Fomsgaard A, Krogfelt KA, Jørgensen CS.
507 2020. Evaluation of nine commercial SARS-CoV-2 immunoassays. medRxiv
508 2020.04.09.20056325.

509 34. Chen Y, Guo Y, Pan Y, Zhao ZJ. 2020. Structure analysis of the receptor binding of 2019-
510 nCoV. Biochemical and Biophysical Research Communications 525:135–140.

511 35. Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, Yu J, Shan S, Zhou B, Song S, Tang X, Yu J, Lan J,
512 Yuan J, Wang H, Zhao J, Zhang S, Wang Y, Shi X, Liu L, Zhao J, Wang X, Zhang Z, Zhang L.
513 2020. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature
514 https://doi.org/10.1038/s41586-020-2380-z.

515 36. Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, Markmann A, Cornaby C,
516 Bartelt L, Weiss S, Park Y, Edwards CE, Weimer E, Scherer EM, Rouphael N, Edupuganti S,
517 Weiskopf D, Tse LV, Hou YJ, Margolis D, Sette A, Collins MH, Schmitz J, Baric RS, de Silva AM.
518 2020. The receptor binding domain of the viral spike protein is an immunodominant and
519 highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol 5:eabc8413.

520 37. Shi R, Shan C, Duan X, Chen Z, Liu P, Song J, Song T, Bi X, Han C, Wu L, Gao G, Hu X, Zhang Y,
521 Tong Z, Huang W, Liu WJ, Wu G, Zhang B, Wang L, Qi J, Feng H, Wang F, Wang Q, Gao GF,
522 Yuan Z, Yan J. 2020. A human neutralizing antibody targets the receptor binding site of
523 SARS-CoV-2. Nature 584:120–124.

524 38. Chia WN, Tan CW, Foo R, Kang AEZ, Peng Y, Sivalingam V, Tiu C, Ong XM, Zhu F, Young BE,
525 Chen MI-C, Tan Y-J, Lye DC, Anderson DE, Wang L-F. 2020. Serological differentiation
526 between COVID-19 and SARS infections. Emerging Microbes & Infections 9:1497–1505.

527 39. Grandjean L, Saso A, Ortiz A, Lam T, Hatcher J, Thistlethwaite R, Harris M, Best T, Johnson M,
528 Wagstaffe H, Ralph E, Mai A, Colijn C, Breuer J, Buckland M, Gilmour K, Goldblatt D, Team
529 TC-SS. 2020. Humoral Response Dynamics Following Infection with SARS-CoV-2. medRxiv
530 2020.07.16.20155663.

531 40. Crawford KHD, Dingens AS, Eguia R, Wolf CR, Wilcox N, Logue JK, Shuey K, Casto AM, Fiala B,
532 Wrenn S, Pettie D, King NP, Greninger AL, Chu HY, Bloom JD. 2020. Dynamics of neutralizing
533 antibody titers in the months after SARS-CoV-2 infection. J Infect Dis jiaa618.

534 41. McAndrews KM, Dowlatshahi DP, Dai J, Becker LM, Hensel J, Snowden LM, Leveille JM,
535 Brunner MR, Holden K, Hopkins NS, Harris A, Kumpati JJ, Whitt MA, Lee JJ, Ostrosky-
536 Zeichner L, Papanna R, LeBleu V, Allison J, Kalluri R. 2020. Heterogeneous antibodies against
537 SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications on COVID-19
538 immunity. JCI Insight https://doi.org/10.1172/jci.insight.142386.

539 42. Bal A, Pozzetto B, Trabaud M-A, Escuret V, Rabilloud M, Langlois-jacques C, Paul A, Guibert
540 N, D'aubarde C, Massardier A, Boibieux A, Morfin F, Pitiot V, Gueyffier F, Lina B, Fassier JB,
541 Assant S. 2020. Evaluation of high-throughput SARS-CoV-2 serological assays in a
542 longitudinal cohort of mild COVID-19 patients: sensitivity, specificity and association with
543 virus neutralization test. medRxiv 2020.09.30.20194290.

544 43. He Y, Zhu Q, Liu S, Zhou Y, Yang B, Li J, Jiang S. 2005. Identification of a critical neutralization
545 determinant of severe acute respiratory syndrome (SARS)-associated coronavirus:
546 importance for designing SARS vaccines. Virology 334:74–82.

547 44. Cao Z, Liu L, Du L, Zhang C, Jiang S, Li T, He Y. 2010. Potent and persistent antibody
548 responses against the receptor-binding domain of SARS-CoV spike protein in recovered
549 patients. Virol J 7:299.

550 45. Li L, Tong X, Chen H, He R, Lv Q, Yang R, Zhao L, Wang J, Xu H, Liu C, Chen G, Chen S, Li C,
551 Qiao J, Yang J, Wu Y, Liu Z. 2020. Characteristics and serological patterns of COVID-19
552 convalescent plasma donors: optimal donors and timing of donation. Transfusion
553 https://doi.org/10.1111/trf.15918.

554 46. Salazar E, Kuchipudi SV, Christensen PA, Eagar TN, Yi X, Zhao P, Jin Z, Long SW, Olsen RJ,
555 Chen J, Castillo B, Leveque C, Towers DM, Lavinder J, Gollihar JD, Cardona J, Ippolito GC,
556 Nissly RH, Bird IM, Greenawalt D, Rossi RM, Gontu A, Srinivasan S, Poojary IB, Cattadori IM,
557 Hudson PJ, Joselyn N, Prugar L, Huie K, Herbert A, Bernard DW, Dye J, Kapur V, Musser JM.
558 2020. Relationship between Anti-Spike Protein Antibody Titers and SARS-CoV-2 In Vitro

559 Virus Neutralization in Convalescent Plasma. bioRxiv
560 https://doi.org/10.1101/2020.06.08.138990.

561 47. Yao X-Y, Liu W, Li Z-Y, Xiong H-L, Su Y-Y, Li T, Zhang S-Y, Zhang X-J, Bi Z-F, Deng C-X, Li C-Y,
562 Yuan Q, Zhang J, Zhang T-Y, Wang Z-X, Ge S, Ningshao X. 2020. Neutralizing and binding
563 antibody kinetics of COVID-19 patients during hospital and convalescent phases. medRxiv
564 2020.07.18.20156810.

565 48. Pepper M, Rodda L, Netland J, Shehata L, Pruner K, Morawski P, Thouvenel C, Takahara K,
566 Eggenberger J, Hemann E, Waterman H, Fahning M, Chen Y, Rathe J, Stokes C, Wrenn S,
567 Fiala B, Carter L, Hamerman J, King N, Gale M, Campbell D, Rawlings D. 2020. Functional
568 SARS-CoV-2-specific immune memory persists after mild COVID-19. Res Sq
569 https://doi.org/10.21203/rs.3.rs-57112/v1.

570 49. Dagotto G, Yu J, Barouch DH. 2020. Approaches and Challenges in SARS-CoV-2 Vaccine
571 Development. Cell Host Microbe https://doi.org/10.1016/j.chom.2020.08.002.

572 50. Amanat F, Krammer F. 2020. SARS-CoV-2 Vaccines: Status Report. Immunity 52:583–589.

573 51. Bryan A, Pepper G, Wener MH, Fink SL, Morishima C, Chaudhary A, Jerome KR, Mathias PC,
574 Greninger AL. 2020. Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG
575 Assay and Seroprevalence in Boise, Idaho. J Clin Microbiol
576 https://doi.org/10.1128/JCM.00941-20.

577 52. Tang MS, Hock KG, Logsdon NM, Hayes JE, Gronowski AM, Anderson NW, Farnsworth CW.
578 2020. Clinical Performance of Two SARS-CoV-2 Serologic Assays. Clinical Chemistry hvaa120.

579 53. Perkmann T, Perkmann-Nagele N, Breyer M-K, Breyer-Kohansal R, Burghuber OC, Hartl S,
580 Aletaha D, Sieghart D, Quehenberger P, Marculescu R, Mucher P, Strassl R, Wagner OF,
581 Binder CJ, Haslacher H. 2020. Side by side comparison of three fully automated SARS-CoV-2
582 antibody assays with a focus on specificity. Clin Chem
583 https://doi.org/10.1093/clinchem/hvaa198.

584 54. Herroelen PH, Martens GA, De Smet D, Swaerts K, Decavele A-S. 2020. Humoral Immune
585 Response to SARS-CoV-2: Comparative Clinical Performance of Seven Commercial Serology
586 Tests. American Journal of Clinical Pathology aqaa140.

587 55. Pflüger LS, Bannasch JH, Brehm TT, Pfefferle S, Hoffmann A, Nörz D, van der Meirschen M,
588 Kluge S, Haddad M, Pischke S, Hiller J, Addo MM, Lohse AW, Wiesch JS zur, Peine S,
589 Aepfelbacher M, Lütgehetmann M. 2020. Clinical evaluation of five different automated
590 SARS-CoV-2 serology assays in a cohort of hospitalized COVID-19 patients. Journal of Clinical
591 Virology 130:104549.

592 56. Wolff F, Dahma H, Duterme C, Van den Wijngaert S, Vandenberg O, Cotton F, Montesinos I.
593 2020. Monitoring antibody response following SARS-CoV-2 infection: diagnostic efficiency of
594 4 automated immunoassays. Diagn Microbiol Infect Dis 98:115140.

595 57. Trabaud M-A, Icard V, Milon M-P, Bal A, Lina B, Escuret V. 2020. Comparison of eight
596 commercial, high-throughput, automated or ELISA assays detecting SARS-CoV-2 IgG or total
597 antibody. J Clin Virol 132:104613.

598 58. Xiao AT, Gao C, Zhang S. 2020. Profile of specific antibodies to SARS-CoV-2: The first report. J
599 Infect 81:147–178.

600 59. Padoan A, Cosma C, Sciacovelli L, Faggian D, Plebani M. 2020. Analytical performances of a
601 chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and antibody kinetics. Clinical
602 Chemistry and Laboratory Medicine (CCLM) 1.

603 60. Suhandynata RT, Hoffman MA, Kelner MJ, McLawhon RW, Reed SL, Fitzgerald RL. 2020.
604 Longitudinal Monitoring of SARS-CoV-2 IgM and IgG Seropositivity to Detect COVID-19. The
605 Journal of Applied Laboratory Medicine jfaa079.

606 61. Sun B, Feng Y, Mo X, Zheng P, Wang Q, Li P, Peng P, Liu X, Chen Z, Huang H, Zhang F, Luo W,
607 Niu X, Hu P, Wang L, Peng H, Huang Z, Feng L, Li F, Zhang F, Li F, Zhong N, Chen L. 2020.
608 Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. Emerg
609 Microbes Infect 9:940–948.

610 62. Long Q-X, Liu B-Z, Deng H-J, Wu G-C, Deng K, Chen Y-K, Liao P, Qiu J-F, Lin Y, Cai X-F, Wang
611 D-Q, Hu Y, Ren J-H, Tang N, Xu Y-Y, Yu L-H, Mo Z, Gong F, Zhang X-L, Tian W-G, Hu L, Zhang
612 X-X, Xiang J-L, Du H-X, Liu H-W, Lang C-H, Luo X-H, Wu S-B, Cui X-P, Zhou Z, Zhu M-M, Wang
613 J, Xue C-J, Li X-F, Wang L, Li Z-J, Wang K, Niu C-C, Yang Q-J, Tang X-J, Zhang Y, Liu X-M, Li J-J,
614 Zhang D-C, Zhang F, Liu P, Yuan J, Li Q, Hu J-L, Chen J, Huang A-L. 2020. Antibody responses
615 to SARS-CoV-2 in patients with COVID-19. Nat Med 26:845–848.

616 63. Yongchen Z, Shen H, Wang X, Shi X, Li Y, Yan J, Chen Y, Gu B. 2020. Different longitudinal
617 patterns of nucleic acid and serology testing results based on disease severity of COVID-19
618 patients. Emerging Microbes & Infections 9:833–836.

619 64. Wang X, Guo X, Xin Q, Pan Y, Hu Y, Li J, Chu Y, Feng Y, Wang Q. 2020. Neutralizing Antibodies
620 Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients. Clin Infect Dis
621 https://doi.org/10.1093/cid/ciaa721.

622 65. Hansen CB, Jarlhelt I, Pérez-Alós L, Hummelshøj Landsy L, Loftager M, Rosbjerg A,
623 Helgstrand C, Bjelke JR, Egebjerg T, Jardine JG, Sværke Jørgensen C, Iversen K, Bayarri-Olmos
624 R, Garred P, Skjoedt M-O. 2020. SARS-CoV-2 antibody responses determine disease severity
625 in COVID-19 infected individuals. medRxiv 2020.07.27.20162321.

626

627

628 **FIGURE LEGENDS**

629

630 **Figure 1. Study flow diagram.** Description of SARS-CoV-2-positive samples used to determine
631 the positive percent agreement relative to the time of RT-PCR-positive test result and to the
632 time of symptom onset. The number of and reason for sample exclusion are indicated in the
633 white boxes. Included samples are indicated in greyed boxes. Altogether, out of the 405
634 collected samples (from 142 SARS-CoV-2-positive patients), 232 samples from 130 patients with
635 a documented date for the SARS-CoV-2-specific PCR-positive test, and 105 samples from 63
636 patients with a documented date of symptom onset were tested with both VIDAS® SARS-CoV-2
637 IgM and IgG assays (paired tests).

638

639 **Figure 2. Distribution of IgM (A) and IgG (B) index values obtained using the VIDAS® SARS-CoV-**
640 **2 IgM and IgG assays, respectively, in patients confirmed positive for SARS-CoV-2, according to**
641 **the time from symptom onset.** VIDAS® SARS-CoV-2 IgM and IgG index values of 105 paired tests
642 from 63 SARS-CoV-2-positive patients (Table 4, Table 2 and Fig. 1) are displayed as Tukey box
643 plots according to the time from symptom onset. No more than one patient's sample is included
644 per time frame. The number of tested samples (N), and the median and interquartile range
645 (IQR) of index values are indicated below each graph. The dashed line shows the positivity cut-
646 off of both assays (i = 1.00).

647

648 **Figure 3. Distribution of IgM (A) and IgG (B) index values obtained using the VIDAS® SARS-CoV-**
649 **2 IgM and IgG assays, respectively, in hospitalized vs. non-hospitalized patients confirmed**
650 **positive for SARS-CoV-2, according to the time from PCR-positive result.** Out of the 232 paired
651 tests (Table 3), 15 were from patients with an unknown hospitalization status (Table 2) and
652 were thus excluded from the analysis. VIDAS® SARS-CoV-2 IgM and IgG index values of 217
653 paired tests from 115 SARS-CoV-2-positive patients (100 samples from 54 hospitalized patients
654 and 117 samples from 61 non-hospitalized patients) are depicted as Tukey box plots according
655 to the time from RT-PCR-positive test result. No more than one patient's sample is included per
656 time frame. The number of tested samples (N) and the median index are indicated below each
657 graph. The dashed line shows the positivity cut-off of both assays (i = 1.00). Differences between
658 the groups of hospitalized and non-hospitalized patients were tested at each time frame (0-7, 8-
659 15, 16-23 days post positive PCR) using a two-sided MWU-test; the respective p-values are
660 displayed above each graph. No statistical testing was performed at 24-31 and ≥ 32 days due to
661 the too low N values, notably in the group of non-hospitalized patients.

662

663 **Figure 4. Kinetics of IgM and IgG seroconversion in four selected hospitalized patients.** VIDAS®
664 SARS-CoV-2 IgM and IgG index values of four patients (A to D, respectively) measured over time
665 after symptom onset are presented. The dashed line indicates the positivity cut-off of both
666 assays (i = 1.00). Further patients' information is as follows: (**A**) the 78-year-old male patient
667 was in the intensive-care unit (ICU) at all investigated time points, except at the first (day 7) and
668 last (day 33) measurement time points; (**B**) the 77-year-old male patient was in ICU at all
669 investigated time points; (**C**) the 43-year-old male patient was in ICU at all investigated times,

670 except at the last two measurement time points (day 71 and 74); (**D**) the 67-year-old male

671 patient was in ICU at all investigated time points.

672

673 **Table 1. Cross-reactivity of human sera from patients with other infections or medical**

674 **conditions potentially interfering with the VIDAS® SARS-CoV-2 IgM and IgG assays**

Sample category	VIDAS® SARS-CoV-2 IgM		VIDAS® SARS-CoV-2 IgG	
	No. samples tested	No. positive tests	No. samples tested	No. positive tests
Pregnant women	5	0	5	0
Antinuclear antibody (ANA)[a]	47	2	47	0
Rheumatoid factor	19	4	19	0
Human anti-mouse antibody (HAMA)	5	0	5	0
Borrelia burgdorferi [b]	10	0	6	0
Haemophilus Influenzae B	5	0	5	0
Plasmodium falciparum	3	1	3	0
Toxoplasma gondii [b]	10	0	6	0
Treponema pallidum	3	0	3	0
Trypanosoma cruzi	5	1	5	0
Hepatitis A virus (HAV)	3	0	3	0
Hepatitis B virus (HBV)	5	0	5	0
Hepatitis C virus (HCV)	5	0	5	0
Hepatitis E virus (HEV)[b]	7	0	6	0
Herpes simplex virus (HSV)[b]	6	0	6	0
Human immunodeficiency virus (HIV)	5	0	5	1
Cytomegalovirus (CMV)	4	0	3	0
Measles virus (MV)	4	0	3	0
Mumps virus (MuV)	1	0	3	0
Rubella virus (RuV)[b]	10	0	6	0
Dengue virus (DENV)	3	0	3	0
West Nile virus (WNV)	4	0	3	0
Yellow fever virus (YFV)	4	0	3	0
Zika virus (ZIKV)[b]	5	0	5	0
Adenovirus (AdV)	2	0	2	0
Metapneumovirus (MPV)	4	0	4	0
Rhinovirus/Enterovirus (RV/EnteroV)[c]	20	1	20	0
Influenza A and B virus (IAV/IBV)	30	0	30	0
Parainfluenza viruses 1/2/3 (PIV-1/2/3)	11	0	11	0
Respiratory syncytial virus A or B (RSV A or B)	13	0	13	1
Coronavirus NL63/HKU1 (CoV-NL63/HKU1)[d]	9	1	9	0
Coronavirus 229E (CoV-229E)	7	0	7	0
Coronavirus OC43 (CoV-OC43)	2	0	2	0
Total	**276**	**10**	**261**	**2**

675 [a]Include anti-DNA, anti-SSA, anti-SSB and anti-Sm/RNP antibodies; [b]The proportion of acute infection (i.e. IgM-positive for the
676 respective infectious agent, when IgM levels were characterized) among samples tested with the VIDAS® SARS-CoV-2 IgM assay was:
677 Borrelia burgdorferi: 5/10, Toxoplasma gondii: 5/10, HEV: 3/7, HSV: 3/6, RuV: 5/10, ZIKV: 3/5; [c]One out of 20 sera was from a patient
678 with a bocavirus (BoV) co-infection and was negative in both VIDAS® SARS-CoV-2 IgM and IgG assays; [d]Six out of the nine sera tested
679 were from patients positive for CoV-NL63 and three were from patients positive for CoV-NL63 and/or CoV-HKU1.

680 **Table 2. Demographics of French patients positive for SARS-CoV-2 used for the determination**

681 **of VIDAS® SARS-CoV-2 IgM and IgG sensitivity (positive percent agreement with RT-PCR**

682 **positivity)**

VIDAS® SARS-CoV-2 serology testing	IgM	IgG	Combined IgM/IgG
Patients with documented date of RT-PCR-positive test			
Number of samples tested	234	253	232
Study population, N (%)	132 (100%)	139 (100%)	130 (100%)
Age in years, median (range)			
Non-hospitalized (N=61)	missing	missing	missing
Other (N=71/78/69)	71 (27-96)	70.5 (27-96)	70 (27-96)
Gender, N (%)			
Male	47 (35.6%)	53 (38.1%)	47 (36.2%)
Female	24 (18.2%)	25 (18.0%)	22 (16.9%)
Missing	61 (46.2%)	61 (43.9%)	61 (46.9%)
Disease severity, N (%)			
Hospitalized	56 (42.4%)	57 (41.0%)	54 (41.55%)
Non-hospitalized	61 (46.2%)	61 (43.9%)	61 (46.9%)
Missing	15 (11.4%)	21 (15.1%)	15 (11.55%)
Patients with documented date of symptom onset			
Number of samples tested	108	113	105
Study population, N (%)	65 (100%)	71 (100%)	63 (100%)
Age in years, median (range)	70 (27-96)	70 (27-96)	70 (27-96)
Gender, N (%)			
Male	45 (69.2%)	51 (71.8%)	45 (71.4%)
Female	20 (30.8%)	20 (28.2%)	18 (28.6%)
Disease severity, N (%)			
Hospitalized	50 (76.9%)	50 (70.4%)	48 (76.2%)
Non-hospitalized[a]	0 (0.00%)	0 (0.0%)	0 (0.0%)
Missing	15 (23.1%)	21 (29.6%)	15 (23.8%)

683 [a]Date of symptom onset not documented in non-hospitalized COVID-19 patients

684

685 **Table 3. Positive percent agreement (PPA) of the VIDAS® SARS-CoV-2 IgM, IgG and combined**

686 **IgM/IgG test results of SARS-CoV-2-positive samples, according to the time from RT-PCR-**

687 **positive result**

VIDAS® SARS-CoV-2 serology testing	Time from RT-PCR-positive result	Median (range) time in days	No. samples[a]	No. positive results	PPA	95% CI
IgM (N=232)	0-7 days	2 (0-7)	110	49	44.5%	35.6-53.9%
	8-15 days	14 (8-15)	60	49	81.7%	70.1-89.4%
	16-23 days	20 (16-23)	38	31	81.6%	66.6-90.8%
	24-31 days	26 (24-28)	13	13	100.0%	75.3-100.0%
	≥ 32 days	33 (32-65)	11	9	81.8%	52.3-94.9%
IgG (N=232)	0-7 days	2 (0-7)	110	50	45.5%	36.5-54.8%
	8-15 days	14 (8-15)	60	53	88.3%	77.8-94.2%
	16-23 days	20 (16-23)	38	36	94.7%	82.7-98.5%
	24-31 days	26 (24-28)	13	13	100.0%	75.3-100.0%
	≥ 32 days	33 (32-65)	11	11	100.0%	71.5-100.0%
Combined IgM/IgG[b] (N=232)	0-7 days	2 (0-7)	110	59	53.6%	44.4-62.7%
	8-15 days	14 (8-15)	60	57	95.0%	86.1-99.0%
	16-23 days	20 (16-23)	38	38	100.0%	90.7-100.0%
	24-31 days	26 (24-28)	13	13	100.0%	75.3-100.0%
	≥ 32 days	33 (32-65)	11	11	100.0%	71.5-100.0%

688 [a]no more than one test result per patient per time period; [b]combined test is positive when at least one of IgM and/or IgG tests are
689 positive

690

691 **Table 4. Positive percent agreement (PPA) of the VIDAS® SARS-CoV-2 IgM, IgG and combined**

692 **IgM/IgG test results of SARS-CoV-2-positive samples, according to the time from symptom**

693 **onset**

VIDAS® SARS-CoV-2 serology testing	Time from symptom onset	Median (range) time in days	No. samples[a]	No. positive results	PPA	95% CI
IgM (N=105)	0-7 days	5.5 (1-7)	22	7	31.8%	16.4-52.7%
	8-15 days	12 (8-15)	29	24	82.8%	65.5-92.4%
	16-23 days	18 (16-23)	26	26	100.0%	86.8-100.0%
	24-31 days	26 (24-30)	18	18	100.0%	81.5-100.0%
	≥ 32 days	35 (32-65)	10	10	100.0%	69.2-100.0%
IgG (N=105)	0-7 days	5.5 (1-7)	22	7	31.8%	16.4-52.7%
	8-15 days	12 (8-15)	29	25	86.2%	69.4-94.5%
	16-23 days	18 (16-23)	26	25	96.2%	80.4-99.9%
	24-31 days	26 (24-30)	18	17	94.4%	74.2-99.0%
	≥ 32 days	35 (32-65)	10	10	100.0%	69.2-100.0%
Combined IgM/IgG[b] (N=105)	0-7 days	5.5 (1-7)	22	8	36.4%	19.7-57.0%
	8-15 days	12 (8-15)	29	26	89.7%	73.6-96.4%
	16-23 days	18 (16-23)	26	26	100.0%	86.8-100.0%
	24-31 days	26 (24-30)	18	18	100.0%	81.5-100.0%
	≥ 32 days	35 (32-65)	10	10	100.0%	69.2-100.0%

694 [a]no more than one test result per patient per time period; [b]combined test is positive when at least one of IgM and/or IgG tests are
695 positive

696

697 **Table 5. Positive and negative predictive values (PPV/NPV) at 5% prevalence of the VIDAS®**

698 **SARS-CoV-2 IgM, IgG and combined IgM/IgG test results, according to the time from symptom**

699 **onset**

VIDAS® SARS-CoV-2 serology testing	Time from symptom onset	PPV[a] (95% CI)	NPV[a] (95% CI)
IgM	0-7 days	72.1% (36.3-92.1%)	96.5% (95.4-97.4%)
	8-15 days	87.0% (62.5-96.4%)	99.1% (98.0-99.6%)
	16-23 days	89.0% (67.1-97.0%)	100.0% (N/A)[b]
	24-31 days	89.0% (67.1-97.0%)	100.0% (N/A)[b]
	≥ 32 days	89.0% (67.1-97.0%)	100.0% (N/A)[b]
IgG	0-7 days	100.0% (N/A)[b]	96.5% (95.4-97.4%)
	8-15 days	100.0% (N/A)[b]	99.3% (98.2-99.7%)
	16-23 days	100.0% (N/A)[b]	99.8% (98.6-100.0%)
	24-31 days	100.0% (N/A)[b]	99.7% (98.1-100.0%)
	≥ 32 days	100.0% (N/A)[b]	100.0% (N/A)[b]
Combined IgM/IgG	0-7 days	74.7% (40-92.9%)	96.7% (95.6-97.6%)
	8-15 days	87.9% (64.5-96.7%)	99.5% (98.4-99.8%)
	16-23 days	89.0% (67.1-97.0%)	100.0% (N/A)[b]
	24-31 days	89.0% (67.1-97.0%)	100.0% (N/A)[b]
	≥ 32 days	89.0% (67.1-97.0%)	100.0% (N/A)[b]

700 [a]PPV and NPV were calculated at 5% prevalence and using values of specificity and sensitivity (PPA) determined on paired
701 VIDAS® SARS-CoV-2 IgM and IgG test results (N=308 for specificity, Table S3; N=105 for PPA, Table 4); [b]95% CI not calculable
702 (division by zero)

703


N=405 samples of SARS-CoV-2-PCR-positive COVID-19 patients (n=142 patients)
N=2 samples excluded (n=1 patient)
• Missing date of PCR-positive test result
N=194 samples excluded (n=69 patients)
• Missing date of symptom onset
N=403 samples of SARS-CoV-2-PCR-positive COVID-19 patients with documented date of PCR-positive test (n=141 patients)
N=211 samples of SARS-CoV-2-PCR-positive COVID-19 patients with documented date of symptom onset (n=73 patients)
N=169 samples excluded
• IgM test not done (N=34)
• Multiple measurements per patient in one time frame (N=135)
N=150 samples excluded
• IgG test not done (N=6)
• Multiple measurements per patient in one time frame (N=144)
N=103 samples excluded
• IgM test not done (N=9)
• Multiple measurements per patient in one time frame (N=94)
N=98 samples excluded
• IgG test not done (N=6)
• Multiple measurements per patient in one time frame (N=92)
N=234 samples tested with VIDAS® SARS-CoV-2 IgM (n=132 patients)
N=253 samples tested with VIDAS® SARS-CoV-2 IgG (n=139 patients)
N=108 samples tested with VIDAS® SARS-CoV-2 IgM (n=65 patients)
N=113 samples tested with VIDAS® SARS-CoV-2 IgG (n=71 patients)
N=2 samples excluded
• Missing IgG paired tests
N=21 samples excluded
• Missing IgM paired tests
N=3 samples excluded
• Missing IgG paired tests
N=8 samples excluded
• Missing IgM paired tests
N=232 samples tested with both VIDAS® SARS-CoV-2 IgM and IgG assays (n=130 patients)
N=105 samples tested with both VIDAS® SARS-CoV-2 IgM and IgG assays (n=63 patients)

Figure 1



N	22	29	26	18	10
Median (IQR)	0.2 (0.1-1.9)	4.6 (1.9-13)	8.2 (5.9-14)	4.0 (2.7-10)	4.8 (2.0-7.2)



N	22	29	26	18	10
Median (IQR)	0.2 (0.0-1.4)	7.7 (2.1-21)	24.8 (15-33)	28.1 (19-36)	33.2 (28-37)

Figure 2


A
IgM
B
IgG
Hospitalized
Non-hospitalized
P=0.011
P=0.006
P=0.002
P<0.001
P<0.001
P<0.001
VIDAS SARS-CoV-2 IgM index
VIDAS SARS-CoV-2 IgG index
N 49 61 19 34 12 20 10 2 10 0
Median 1.9 0.2 8.1 2.1 8.5 2.0 4.8 2.1 1.8 -
N 49 61 19 34 12 20 10 2 10 0
Median 2.4 0.1 25.7 4.1 32.8 6.6 34.5 9.5 33.3 -
0-7
8-15
16-23
24-31
≥ 32
Days from RT-PCR-positive test result

Figure 3


A
B
C
D
VIDAS SARS-CoV-2 index
Days from symptom onset
IgM
IgG
0
5
10
15
20
25
30
35
40
0
10
20
30
40
50
60
70
80

Figure 4